Randomized Trialhigh evidence

Trevogrumab (anti-GDF8) with or without garetosmab (anti-activin A) for prevention of muscle loss during semaglutide-induced weight reduction in people with obesity (COURAGE): a two-part, phase 2, double-blind, placebo-controlled, randomised trial.

Lancet (London, England)·November 11, 2026·PMID 43014326

Why it matters

GLP-1 receptor agonists cause substantial muscle loss, which may impair physical function and metabolic health. This trial provides proof of concept that inhibiting myostatin/activin signaling can preserve lean mass during weight loss, potentially improving long-term outcomes for patients with obesity.

Infographic summary of Trevogrumab (anti-GDF8) with or without garetosmab (anti-activin A) for prevention of muscle loss during semaglutide-induced weight reduction in people with obesity (COURAGE): a two-part, phase 2, double-blind, placebo-controlled, randomised trial.
Visual abstract · MedLit

The papers that matter, first.

MedLit ranks the medical literature into a specialty feed with concise summaries, evidence-aware triage, and visual takeaways.

§

MedLit · Evidence, Distilled